News
VALN
7.81
-3.93%
-0.32
Weekly Report: what happened at VALN last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at VALN last week (0401-0405)?
Weekly Report · 04/08 09:18
Weekly Report: what happened at VALN last week (0325-0329)?
Weekly Report · 04/01 09:17
Buy Rating on Valneva Supported by Promising Vaccine Developments and Solid Revenue Projections
TipRanks · 03/26 13:25
Valneva SE Files Key Financial Documents for 2023
TipRanks · 03/26 11:58
Valneva Announces The Initiation Of Phase 1 Trial Of Second-Generation Zika Vaccine Candidate
The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to 49 years in the United States. Topline data from the trial are expected in the first half of 2025. Participants will receive a low, medium or high dose of VLA 1601.
Benzinga · 03/26 07:14
Weekly Report: what happened at VALN last week (0318-0322)?
Weekly Report · 03/25 09:17
Valneva Is Maintained at Buy by Guggenheim
Dow Jones · 03/22 18:09
Valneva Price Target Cut to $17.00/Share From $18.00 by Guggenheim
Dow Jones · 03/22 18:09
What Analysts Are Saying About Valneva Stock
Valneva (NASDAQ:VALN) underwent analysis by 4 analysts in the last quarter. The average price target for Valneva is $23.75. The company is a vaccine company focused on developing life-saving vaccines. The analysts have provided 12-month price targets of $26.00 for the company.
Benzinga · 03/22 18:01
Guggenheim Maintains Buy on Valneva, Lowers Price Target to $17
Benzinga · 03/22 17:59
Valneva Highlights Vaccine Advances at World Congress
TipRanks · 03/22 11:00
Buy Rating Affirmed for Valneva: Strong Core Growth and Strategic Financial Health
TipRanks · 03/21 10:16
CuriosityStream Inc. declares $0.025 dividend
Seeking Alpha · 03/20 20:38
Valneva SE Announces Strong Financial Growth and R&D Progress
TipRanks · 03/20 17:57
VALN Stock Earnings: Valneva Misses Revenue for Q4 2023
Valneva reported earnings per share of -50 cents for the fourth quarter of 2023. The company reported revenue of $45.10 million. Valneva's revenue was 42.02% worse than the analyst estimate for the same period. The stock is down 2% today.
Investorplace · 03/20 16:53
Valneva GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidance
Valneva reports FY GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidance. Valneva’s total product sales reached €144.6 million in 2023 compared to €114.8 million in 2022.
Seeking Alpha · 03/20 08:13
Valneva Raised 2024 Product Sales Guidance To €160M-€180M (Prior €150M-€180M); Sees Total Revenues Of €170M-€190M
Valneva raises its 2024 product sales4 guidance to between €160 million and €180 million due to improved outlook for IXIARO supply constraints. Total revenues are now expected to reach between €170 million to €190 million in 2024. Valneva anticipates lower R&D expenses than previously communicated.
Benzinga · 03/20 06:32
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Shares of National CineMedia, Inc. Jumped 25.5% to $5.30 after posting upbeat results for fourth quarter. Fusion Pharmaceuticals Inc. Shares jumped 97.3% after the company agreed to be acquired by AstraZeneca. The Dow Jones index gained 75 points on Tuesday.
Benzinga · 03/19 14:03
Valneva Postpones Debt Payments, Eyes Profitability
TipRanks · 03/19 10:57
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.